相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
Filippo Pederzoli et al.
EUROPEAN UROLOGY (2021)
C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma
Niklas Klumper et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Ashley M. Hopkins et al.
EUROPEAN UROLOGY (2020)
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
T. B. Powles et al.
ANNALS OF ONCOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Aly-Khan A. Lalani et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer
Yuichi Ozawa et al.
MEDICAL ONCOLOGY (2019)
Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma
Hiroki Ishihara et al.
TARGETED ONCOLOGY (2019)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
Yosuke Yasuda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study.
Peter H. O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
C-reactive protein as a biomarker for urological cancers
Kazutaka Saito et al.
NATURE REVIEWS UROLOGY (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell Carcinoma
Kazutaka Saito et al.
EUROPEAN UROLOGY (2009)
Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer
Sara Ramsey et al.
BJU INTERNATIONAL (2008)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
C-reactive protein: a critical update
MB Pepys et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
分享论文
